KRAS Mutation-Induced Upregulation of PD-L1 Mediates Immune Escape in Human Lung Adenocarcinoma

Cancer Immunology, Immunotherapy - Germany
doi 10.1007/s00262-017-2005-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P2.09-04 PD-L1 Expression in Primary Lung Adenocarcinoma and Its Relation With EGFR / KRAS Mutation and Clinicopathological Features

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-L1 Upregulation Drives Escape From Anti-Ctla4 and Radiation Therapy

Cancer Discovery
Oncology
2015English

Exosomal PD-L1 Promotes Tumor Growth Through Immune Escape in Non-Small Cell Lung Cancer

Experimental and Molecular Medicine
BiochemistryMedicineClinical BiochemistryMolecular BiologyMolecular Medicine
2019English

Multiple Primary Lung Cancers Containing Adenocarcinoma With EGFR Gene Mutation and Adenocarcinoma With Strong PD-L1 Positivity

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2018English

MicroRNA-155-5p Suppresses PD-L1 Expression in Lung Adenocarcinoma

FEBS Open Bio
BiochemistryGeneticsMolecular Biology
2020English

790 Lipogenesis Governs PD-L1-dependent Immune Escape to Promote Melanoma Growth

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

P2.01-114 the Correlation Among PD-L1 Expression, TMB and Lung Immune Prognostic Index in Chinese Patients With Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2014English

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy